Purple Biotech Ltd's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical and biotechnology firms, universities, governmental entities, and others, many of which possess greater research and development capabilities, human resources, budgets, and marketing, manufacturing, financial, and managerial resources. Competitors with leading therapeutic candidates include IM1240, IM1305, CM24, and NT219. Acquisitions or investments by large corporations in competing companies may further enhance these competitors' resources. The company's clinical trials also compete with other trials for therapeutic candidates within the same therapeutic areas, potentially reducing patient availability and delaying trial progress. Additionally, established alternative therapies for the targeted diseases and conditions may limit market acceptance of the company's products.
October 29, 2025
Purple Biotech Celebrates Manufacturing Milestone for IM1240: A Tri-Specific Antibody from the CAPTN-3 Platform Purple Biotech, a leading biopharmaceutical company focused on developing innovative therapies for cancer treatment, has made significant strides with its latest achievement in the manufacturing of IM1240, a tri-specific antibody derived from the CAPTN-3 platform. This breakthrough has garnered considerable attention as it not only demonstrates the company s commitment to advancing cancer therapies but also positions IM1240 competitively for future clinical development and commercialization. Achieving Commercially Viable Yield The announcement marks a pivotal moment in the lifecycle of IM1240, with...
June 27, 2024
Purple Biotech Ltd., a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently announced additional positive interim results from its randomized Phase 2 study of CM24. The study evaluates the combination of CM24 with Bristol Myers Squibb s immune checkpoint inhibitor nivolumab and standard of care chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. These results have shed light on the potential role of serum MPO as a predictive biomarker for improved overall survival in the treated patient population.The Study:The Phase 2 study (NCT 04731467) conducted by Purple Biotech is an open-label, multicenter trial comparing the co...
April 25, 2024
In an exciting advancement for pancreatic cancer therapeutics, Purple Biotech has been selected to present a late-breaking abstract poster at the prestigious American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The selected study pertains to the interim results obtained from the randomized Phase 2 trial of CM24 in combination with Nivolumab and provides an intriguing insight into its potential as a transformative pancreatic cancer therapeutic.The Phase 2 trial, which is randomized, explores CM24, a first-in-class monoclonal antibody that blocks the immune checkpoint CEACAM1, in patients with metastatic pancreatic ductal adenocarcinoma. As per interim data, standard care- Nal-IRI/5FU/LV in combin...
Sources:
Purple Biotech Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Purple Biotech Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
